皮肤恶性黑色素瘤(CMM)是一种具有高度侵袭性的皮肤恶性肿瘤,早期即可发生淋巴或血行转移,致死率高。早期明确诊断及规范化手术治疗是改善预后的关键。而随着近年来分子靶向治疗和免疫治疗的快速发展,晚期CMM尤其是局部不可切除或转移性患者的治疗效果得到明显改善,但未来仍需不断探索。文章就CMM治疗现状进行综述,以期为临床实践提供参考。Cutaneous malignant melanoma (CMM) is a highly aggressive skin malignancy that can metastasize via the lymphatic or hematogenous routes at an early stage, resulting in a high mortality rate. Early accurate diagnosis and standardized surgical treatment are critical to improving prognosis. With the rapid advancements in molecular targeted therapy and immunotherapy in recent years, the treatment outcomes for advanced CMM, particularly in patients with unresectable or metastatic disease, have significantly improved. However, further exploration is needed in the future. This article reviews the current status of CMM treatment to provide a reference for clinical practice.
暂无评论